Hypothetically, if the drug treatment did add 35 percent to the lifespan of humans, it would bring average life expectancy to between 95 and 100 years.
Scientists and researchers at MIT and Harvard, in collaboration with other university experts, have developed an implantable device that could prevent implanted insulin-producing cells from being attacked.